Newborn screening testing services for brian d. Allgood army community hospital (bdaach), korea
Ended Awarded Last action
- Contract number
- W81K0225FA091
- Awardee
-
Revvity Omics Inc. UEI LDJULX8K6M85 Part of Revvity Inc.
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $4,550
Award facts
- Contract value 100% obligated
- $4,549.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- Defense Health Agency Department of Defense
- NAICS code
- 621511 Medical Laboratories
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Competed under SAP Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- South Korea
Award details come from SAM.gov/FPDS.
About this award
Revvity Omics Inc., operating as Perkinelmer Genetics, received a $4,549.50 firm fixed-price delivery order from the Defense Health Agency for newborn screening testing services at Brian D. Allgood Army Community Hospital in South Korea. This delivery order, awarded on July 1, 2025, with completion scheduled for September 28, 2025, represents a task order issued under Revvity Omics Inc.'s larger Indefinite Delivery Contract valued at $301,668 and awarded to the same facility on September 29, 2024. The contract carries no set-aside designation and is part of the Defense Health Agency's ongoing commitment to providing comprehensive medical diagnostic capabilities to military treatment facilities worldwide.
The newborn screening services delivered under this contract include comprehensive testing panels that evaluate for conditions such as galactosemia, hypothyroidism, cystic fibrosis, glucose-6-phosphate dehydrogenase deficiency, and hemoglobinopathies. Revvity Omics Inc. maintains required CAP/CLIA accreditation and FDA licensing to perform these specialized diagnostic services, with performance standards requiring 72-hour turnaround for initial results and confirmatory testing within 5–10 business days. As a subsidiary of Revvity Inc., the company has established itself as a specialized provider of genetic testing and newborn screening services exclusively to military healthcare agencies across multiple overseas and domestic locations, including Germany, Italy, and various U.S. military installations.
Quick answers
Who was awarded contract W81K0225FA091?
W81K0225FA091 was awarded to Revvity Omics Inc. by Medical Command (Department of the Army) on July 1, 2025.
How much is contract W81K0225FA091 worth?
The government has obligated $4,550 on W81K0225FA091.
Which agency awarded contract W81K0225FA091?
Medical Command (Department of the Army) awarded W81K0225FA091, with funding from Defense Health Agency (Department of Defense).
Is contract W81K0225FA091 an order under another contract?
Yes. W81K0225FA091 is a delivery order under W81K0224D0009, an indefinite delivery contract.
Was contract W81K0225FA091 competed?
The extent of competition for W81K0225FA091 was competed under sap.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award